Switch theme
Sign up to access all valuation multiples
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
2007
838
LTM Revenue $247M
LTM EBITDA -$336M
$853M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Iovance Biotherapeutics has a last 12-month revenue of $247M and a last 12-month EBITDA of -$336M.
In the most recent fiscal year, Iovance Biotherapeutics achieved revenue of $164M and an EBITDA of -$352M.
Iovance Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Iovance Biotherapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $164M | XXX | XXX | XXX |
| Gross Profit | n/a | -$9.6M | XXX | XXX | XXX |
| Gross Margin | NaN% | -6% | XXX | XXX | XXX |
| EBITDA | -$427M | -$352M | XXX | XXX | XXX |
| EBITDA Margin | -35949% | -214% | XXX | XXX | XXX |
| Net Profit | -$396M | -$444M | XXX | XXX | XXX |
| Net Margin | -33296% | -271% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Iovance Biotherapeutics's stock price is $3.
Iovance Biotherapeutics has current market cap of $1.1B, and EV of $853M.
See Iovance Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $853M | $1.1B | XXX | XXX | XXX | XXX | $-1.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Iovance Biotherapeutics has market cap of $1.1B and EV of $853M.
Iovance Biotherapeutics's trades at 3.4x LTM EV/Revenue multiple, and -2.5x LTM EBITDA.
Analysts estimate Iovance Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Iovance Biotherapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $853M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIovance Biotherapeutics's NTM/LTM revenue growth is 118%
Iovance Biotherapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Iovance Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Iovance Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Iovance Biotherapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13699% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -214% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -97% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 172% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 265% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iovance Biotherapeutics acquired XXX companies to date.
Last acquisition by Iovance Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Iovance Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Iovance Biotherapeutics founded? | Iovance Biotherapeutics was founded in 2007. |
| Where is Iovance Biotherapeutics headquartered? | Iovance Biotherapeutics is headquartered in United States of America. |
| How many employees does Iovance Biotherapeutics have? | As of today, Iovance Biotherapeutics has 838 employees. |
| Who is the CEO of Iovance Biotherapeutics? | Iovance Biotherapeutics's CEO is Dr. Frederick G. Vogt, J.D.. |
| Is Iovance Biotherapeutics publicy listed? | Yes, Iovance Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Iovance Biotherapeutics? | Iovance Biotherapeutics trades under IOVA ticker. |
| When did Iovance Biotherapeutics go public? | Iovance Biotherapeutics went public in 2010. |
| Who are competitors of Iovance Biotherapeutics? | Similar companies to Iovance Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Iovance Biotherapeutics? | Iovance Biotherapeutics's current market cap is $1.1B |
| What is the current revenue of Iovance Biotherapeutics? | Iovance Biotherapeutics's last 12-month revenue is $247M. |
| What is the current EBITDA of Iovance Biotherapeutics? | Iovance Biotherapeutics's last 12-month EBITDA is -$336M. |
| What is the current EV/Revenue multiple of Iovance Biotherapeutics? | Current revenue multiple of Iovance Biotherapeutics is 3.4x. |
| What is the current EV/EBITDA multiple of Iovance Biotherapeutics? | Current EBITDA multiple of Iovance Biotherapeutics is -2.5x. |
| What is the current revenue growth of Iovance Biotherapeutics? | Iovance Biotherapeutics revenue growth between 2023 and 2024 was 13699%. |
| Is Iovance Biotherapeutics profitable? | Yes, Iovance Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
